17361-44-3

Usage

Uses

Used in Pesticide Production:
Ditetradecylamine is used as a surfactant and emulsifying agent for enhancing the stability and effectiveness of pesticides. Its ability to lower surface tension aids in the even distribution of the pesticide, ensuring better coverage and protection for crops.
Used in Corrosion Inhibition:
In the industry, ditetradecylamine serves as an effective corrosion inhibitor, utilized to protect metal surfaces from degradation. Its surfactant properties help in forming a protective layer on metal surfaces, thereby reducing the rate of corrosion.
Used in Personal Care Products:
Ditetradecylamine is employed as an ingredient in personal care products, where it acts as an emulsifier. It helps in blending oil and water-based components, creating stable formulations for products such as creams, lotions, and shampoos.
Used in Industrial Formulations:
Ditetradecylamine is used as a surfactant in various industrial formulations to improve the stability of emulsions and suspensions. Its capacity to reduce surface tension is crucial for the successful mixing of non-miscible substances, ensuring the performance and longevity of the final product.
Safety Precautions:
When handling ditetradecylamine, it is important to exercise caution due to its potential to cause skin and eye irritation. Additionally, respiratory irritation may occur if the compound is inhaled, necessitating proper safety measures during its use.

InChI:InChI=1/C28H59N/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h29H,3-28H2,1-2H3

Upstream product

• 2016-42-4 tetradecylamine 
• 2425-54-9 myristyl chloride 
• 112-71-0 1-Bromotetradecane 
• 622-56-0 myristanilide 
• 123-91-1 1,4-dioxane 
• 638-58-4 tetradecanamide 
• 112-64-1 tetradecanoyl chloride 
• 555-45-3 tritetradecanoylglycerol 
• 544-63-8 n-tetradecanoic acid 
• 124-25-4 myristylaldehyde 
• 159458-37-4 thiomyristamide 

Downstream Products

• 41961-81-3 methyl-ditetradecyl-amine 
• 128262-57-7 2,3-Dimethoxy-N,N-ditetradecyl-terephthalamic acid methyl ester 
• 129194-28-1 N,N-ditetradecyl-N^α-(tert-butoxycarbonyl)-L-isoasparagine β-benzyl ester 
• 83824-97-9 N,N-ditetradecyl-N^α-t-butoxycarbonyl-N^im-tosyl-L-histidinamide 
• 116058-81-2 N,N-ditetradecyl-Nα-t-butoxycarbonyl-Nε-benzyloxycarbonyl-L-lysinamide 
• 122020-34-2 3-(2,4-Dimethyl-phenyl)-1,1-ditetradecyl-urea 
• 848872-88-8 {2-[2-(2-ditetradecylcarbamoylmethoxy-acetylamino)-acetylamino]-acetylamino}-acetic acid benzyl ester 
• 83824-99-1 (S)-2-Amino-N,N-ditetradecyl-3-[1-(toluene-4-sulfonyl)-1H-imidazol-4-yl]-propionamide 
• 83824-98-0 N,N-ditetradecyl-N^α-(6-bromohexanoyl)-L-histidinamide 
• 95634-16-5 N,N-ditetradecyl-N^ε-(benzyloxycarbonyl)-L-lysinamide 
• 116058-82-3 N,N-ditetradecyl-Nα-6-bromohexanoyl-Nε-benzyloxycarbonyl-L-lysinamide 
• 116058-83-4 N,N-ditetradecyl-Nα-<6-(trimethylammonio)hexanoyl>-Nε-benzyloxycarbonyl-L-lysinamide bromide 
• 95634-16-5 N,N-ditetradecyl-Nε-benzyloxycarbonyl-L-lysinamide 
• 128262-58-8 2,3-Dimethoxy-N,N-ditetradecyl-terephthalamic acid 

Relevant academic research and scientific papers

Serum Compatible Spermine-Based Cationic Lipids with Nonidentical Hydrocarbon Tails Mediate High Transfection Efficiency

Cationic lipids are widely used as nonviral synthetic vectors for gene delivery as a safer alternative to viral vectors. In this work, a library of L-shaped spermine-based cationic lipids with identical and nonidentical hydrophobic chains having variable carbon lengths (from C10 to C18) was designed and synthesized. These lipids were characterized and the structure-activity relationships of these compounds were determined for DNA binding and transfection ability when formulated as cationic liposomes. The liposomes were then used successfully for the transfection of HEK293T, HeLa, PC3, H460, HepG2, SH-SY5Y and Calu’3 cell lines. The transfection efficiency of lipids with nonidentical hydrocarbon chains was greater than the identical analogue. These reagents exhibited superior efficiency to the commercial reagent, Lipofectamine3000, under both serum-free and 10–40 % serum conditions in HEK293T, HeLa and H460 cell lines. The lipids were not toxic to the tested cell line. The results suggest that L-shaped spermine-based cationic lipids with nonidentical hydrocarbon tails could serve as efficient and safe nonviral vector gene carriers in further in vivo studies.

One-pot reductive amination of carboxylic acids: a sustainable method for primary amine synthesis

The reductive amination of carboxylic acids is a very green, efficient and sustainable method for the production of (bio-based) amines. However, with current technology, this reaction requires two to three reaction steps. Here, we report the first (heterogeneous) catalytic system for the one-pot reductive amination of carboxylic acids to amines, with solely H2 and NH3 as the reactants. This reaction can be performed with relatively cheap ruthenium-tungsten bimetallic catalysts in the green and benign solvent cyclopentyl methyl ether (CPME). Selectivities of up to 99% for the primary amine could be achieved at high conversions. Additionally, the catalyst is recyclable and tolerant for common impurities such as water and cations (e.g. sodium carboxylate).

Selective Transformations of Triglycerides into Fatty Amines, Amides, and Nitriles by using Heterogeneous Catalysis

The use of triglycerides as an important class of biomass is an effective strategy to realize a more sustainable society. Herein, three heterogeneous catalytic methods are reported for the selective one-pot transformation of triglycerides into value-added chemicals: i) the reductive amination of triglycerides into fatty amines with aqueous NH3 under H2 promoted by ZrO2-supported Pt clusters; ii) the amidation of triglycerides under gaseous NH3 catalyzed by high-silica H-beta (Hβ) zeolite at 180 °C; iii) the Hβ-promoted synthesis of nitriles from triglycerides and gaseous NH3 at 220 °C. These methods are widely applicable to the transformation of various triglycerides (C4–C18 skeletons) into the corresponding amines, amides, and nitriles.

NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE

The present invention generally relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

LIPID NANOPARTICLE FORMULATIONS

Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.

Design of Ionizable Lipids to Overcome the Limiting Step of Endosomal Escape: Application in the Intracellular Delivery of mRNA, DNA, and siRNA

The intracellular delivery of nucleic acid molecules is a complex process involving several distinct steps; among these the endosomal escape appeared to be of particular importance for an efficient protein production (or inhibition) into host cells. In the present study, a new series of ionizable vectors, derived from naturally occurring aminoglycoside tobramycin, was prepared using improved synthetic procedures that allow structural variations on the linker and hydrophobic domain levels. Complexes formed between the new ionizable lipids and mRNA, DNA, or siRNA were characterized by cryo-TEM experiments and their transfection potency was evaluated using different cell types. We demonstrated that lead molecule 30, bearing a biodegradable diester linker, formed small complexes with nucleic acids and provided very high transfection efficiency with all nucleic acids and cell types tested. The obtained results suggested that the improved and "universal" delivery properties of 30 resulted from an optimized endosomal escape, through the lipid-mixing mechanism.

NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE

The present invention relates to compositions and methods for inducing adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS

Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and e are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Development of new estradiol-cationic lipid hybrids: Ten-carbon twin chain cationic lipid is a more suitable partner for estradiol to elicit better anticancer activity

The present study illustrates the synthesis and anticancer evaluation of six, ten, twelve and fourteen carbon chain containing cationic lipidated-estradiol hybrids. Previously, we have established the lipidation strategy to introduce anticancer activities in various pharmacophores including estradiol (ES). In this structure activity study the length of the carbon chain is narrowed down between C6-C14 to screen out the most potent anticancer molecule among the class. Among the newly developed ES-cationic lipid conjugates, ten-carbon chain containing derivative, ES-C10 (5c) exhibited 4-12 folds better anticancer activity than the previously established derivative, ES-C8 (5b) in various cancer cells of different origin. Moreover cytotoxicity of this molecule was not observed in non-cancer cells. Notably, in spite of bearing estrogenic moiety, ES-C10 exhibited anticancer activity irrespective of estrogen receptor (ER) expression status. ES-C10 exhibited prominent sub-G0 arrest of cancer cells with concomitant induction of apoptosis and demonstrated significant inhibition of tumor growth in mouse melanoma model. Collectively, ES-C10 exemplifies the development of an anticancer agent with broader activity against cancer cells of different origins.

METHODS AND COMPOSITIONS FOR THE EFFICIENT DELIVERY OF THERAPEUTIC AGENTS TO CELLS AND ANIMALS

The present invention provides methods of carrying out the safe and reliable preparation of lipids comprising quaternary amines. Such lipids are especially suited for introducing therapeutic agents into cells or organisms. In particular, the lipids of the invention are suitable for the efficient transfer of gene therapy agents into mammalian cells or organisms in a cell type specific or tissue specific manner.